Abstract
Background: Iron is an essential micronutrient for bacteria, fungi, and humans; as such, each has evolved specialized iron uptake systems to acquire iron from the extracellular environment.
Objective: To describe complex ‘tug of war’ for iron that has evolved between human hosts and pathogenic microorganisms in the battle for this vital nutrient.
Methods: A review of current literature was performed, to assess current approaches and controversies in iron therapy and chelation in humans.
Results: In humans, sequestration (hiding) of iron from invading pathogens is often successful; however, many pathogens have evolved mechanisms to circumvent this approach.
Conclusion: Clinically, controversy continues whether iron overload or administration of iron results in an increased risk of infection. The administration of iron chelating agents and siderophore- conjugate drugs to infected hosts seems a biologically plausible approach as adjunctive therapy in the treatment of infections caused by pathogens dependent on host iron supply (e.g. tuberculosis, malaria, and many bacterial and fungal pathogens); however, thus far, studies in humans have proved unsuccessful.
Keywords: Infection, iron, nutritional immunity, siderophore, iron overload, iron chelation.
Current Medicinal Chemistry
Title:The Battle for Iron between Humans and Microbes
Volume: 25 Issue: 1
Author(s): Peggy L. Carver*
Affiliation:
- Department of Clinical Pharmacy, University of Michigan, College of Pharmacy, Ann Arbor, MI 48109- 1065,United States
Keywords: Infection, iron, nutritional immunity, siderophore, iron overload, iron chelation.
Abstract: Background: Iron is an essential micronutrient for bacteria, fungi, and humans; as such, each has evolved specialized iron uptake systems to acquire iron from the extracellular environment.
Objective: To describe complex ‘tug of war’ for iron that has evolved between human hosts and pathogenic microorganisms in the battle for this vital nutrient.
Methods: A review of current literature was performed, to assess current approaches and controversies in iron therapy and chelation in humans.
Results: In humans, sequestration (hiding) of iron from invading pathogens is often successful; however, many pathogens have evolved mechanisms to circumvent this approach.
Conclusion: Clinically, controversy continues whether iron overload or administration of iron results in an increased risk of infection. The administration of iron chelating agents and siderophore- conjugate drugs to infected hosts seems a biologically plausible approach as adjunctive therapy in the treatment of infections caused by pathogens dependent on host iron supply (e.g. tuberculosis, malaria, and many bacterial and fungal pathogens); however, thus far, studies in humans have proved unsuccessful.
Export Options
About this article
Cite this article as:
Carver L. Peggy *, The Battle for Iron between Humans and Microbes, Current Medicinal Chemistry 2018; 25 (1) . https://dx.doi.org/10.2174/0929867324666170720110049
DOI https://dx.doi.org/10.2174/0929867324666170720110049 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Specific Biologic Therapy with Tumor Necrosis Factor Inhibitors in Patients with Inflammatory Myopathy
Current Rheumatology Reviews Synthesis, Anticonvulsant and Antimicrobial Activities of Some New [1-(2-Naphthyl)-2-(pyrazol-1-yl)ethanone]oxime Ethers
Medicinal Chemistry Machine Learning and Social Network Analysis Applied to Alzheimer's Disease Biomarkers
Current Topics in Medicinal Chemistry Solubility and Permeability Measurement and Applications in Drug Discovery
Combinatorial Chemistry & High Throughput Screening Synthesis and Medicinal Applications of Benzimidazoles: An Overview
Current Organic Synthesis Cytotoxic, Antiproliferative and Apoptotic Effects of Perillyl Alcohol and Its Biotransformation Metabolite on A549 and HepG2 Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Natural Compounds for Overcoming Multidrug Resistance in Mycobacteria
Recent Patents on Biotechnology The Digenea Parasite Opisthorchis felineus: A Target for the Discovery and Development of Novel Drugs
Infectious Disorders - Drug Targets The Use of Infliximab in Dermatology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Design and In Vitro Evaluation of Five Inhibitors of Mycobacterium Tuberculosis
Letters in Drug Design & Discovery Targeting Iron Acquisition by Mycobacterium tuberculosis
Infectious Disorders - Drug Targets Chemical Composition and Antibacterial Potential of Essential Oils from Artemisia Capillaris, Artemisia Nilagirica, Citrus Limon, Cymbopogon Flexuosus, Hedychium Spicatum and Ocimum Tenuiflorum
The Natural Products Journal Emergence in Pyrazolines: Synthetic and Biological Perspective
The Natural Products Journal Virulence on the Fly: Drosophila melanogaster as a Model Genetic Organism to Decipher Host-Pathogen Interactions
Current Drug Targets Human Immunodeficiency Virus-Mononuclear Phagocyte Interactions:Emerging Avenues of Biomarker Discovery, Modes of Viral Persistence and Disease Pathogenesis
Current HIV Research Entropy Model for Multiplex Drug-Target Interaction Endpoints of Drug Immunotoxicity
Current Topics in Medicinal Chemistry The Asymmetric Pictet – Spengler Reaction
Current Organic Synthesis HIV Genomic Mutations Causing Resistance to Antiretroviral Drugs in Seropositive Sicilians
Current HIV Research DFT Based QSAR/QSPR Models in the Development of Novel Anti-tuberculosis Drugs Targeting Mycobacterium tuberculosis
Current Pharmaceutical Design